The authors use single-cell multiomics and CRISPR/Cas9-mediated loss-of-function studies to identify key transcription factors controlling EMT states and metastasis and defines the transcriptional and chromatin landscape controlling EMT progression in mouse skin SCC.
Abstract
Epithelial-to-mesenchymal transition (EMT) is a dynamic process during which cells lose their epithelial characteristics and acquire mesenchymal traits. In cancer, EMT is closely associated with tumor initiation, progression, invasion, metastasis, and therapy resistance. Rather than being a binary state switch, EMT encompasses a spectrum of tumor states with distinct functional properties. However, the transcription factors (TFs) that govern transitions between these EMT states remain poorly defined. Here, using multi-omic approaches combining single-cell RNA-seq and single-cell ATAC-seq, we delineate the transcriptomic and chromatin landscapes of distinct EMT states in a mouse model of skin squamous cell carcinoma (SCC). Through CRISPR/Cas9-mediated loss-of-function studies coupled with in vitro and in vivo functional assays, we identify TFs regulating specific EMT states. Klf5 and Pitx1 control the early stages of EMT and are essential for metastasis formation. In contrast, Nfatc1 and Creb3l1 act at later stages of EMT. Similar EMT states and regulatory patterns are found in mouse pancreatic adenocarcinoma and human cancers. Altogether, our study defines the transcriptional and chromatin landscape controlling EMT progression in mouse skin SCC, identifies EMT state-specific TFs and highlights their essential roles in regulating metastasis. Epithelial-to-mesenchymal transition (EMT) involves cancer cells shifting between different states linked to tumor progression. Here, the authors use single-cell multiomics and CRISPR/Cas9-mediated loss-of-function studies to identify key transcription factors controlling EMT states and metastasis.
Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.
M. O. Odubote, Chiemeka Elochi Emeribe· bioRxiv· 0 citations
Two pivotal studies published in this issue of JCI provide key insights into how ATR intersects with EMT transcriptional reprogramming and uncovered a role for ATR in ECM stiffness–induced EMT, which was associated with an immunosuppressive tumor microenvironment.
Various epigenetic mechanisms controlling cancer cell‐intrinsic states, cancer cell–TME crosstalk, current epigenetic therapies, and future research directions that may lead to the discovery of new biomarkers and the development of effective epigenetic anticancer therapeutics are discussed.
Ji Hoon Park, Mi-Young Kim· Molecular Oncology· 1 citation
Results implicate TNIK in the mechanisms linking epithelial-mesenchymal plasticity with proliferation and evasion of senescence and provide insights into future strategies for the clinical deployment of TNIK inhibitors in LUSC and other TNIK-dependent malignancies.
Mohaddase Hamidi, Kenneth O. Omolo, Korrey W. Hart et al.· bioRxiv· 0 citations
Breast cancer is a heterogeneous disease in which a single oncogenic driver can give rise to divergent tumor phenotypes. How oncogenic mutations generate epithelial state plasticity and coordinately remodel the surrounding tissue remains incompletely understood. Here, we applied longitudinal single cell RNA-sequencing...
Jennifer T. Le, Eun K. Kim, Vasudha Srivastava et al.· bioRxiv· 0 citations
Cisplatin resistance in HGSOC is encoded in discrete IRF1-driven epithelial states that are supported by specific TME communication networks and a glycosaminoglycan–glycolysis metabolic axis, which yields testable biomarkers and therapeutic targets for overcoming platinum resistance in ovarian cancer.
Zhaoyang Jia, Wen-Jing Pan, Xibo Zhao et al.· Cancer Informatics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.